FDA Buzz Halts Sarepta Therapeutics Inc (SRPT)

The FDA's Janet Woodcock seeming spoke out in favor of Sarepta Therapeutics Inc's (NASDAQ:SRPT) muscular dystrophy treatment on Monday

Apr 25, 2016 at 3:36 PM
facebook twitter linkedin

Sarepta Therapeutics Inc (NASDAQ:SRPT) was halted before the market opened, as speculation continues to swirl surrounding the Food and Drug Administration's (FDA) decision on the company's muscular dystrophy treatment, eteplirsen. Just this morning, the FDA's director of drug evaluation, Janet Woodcock, told an FDA-approved panel that it could be harmful ​not ​to approve a drug that works  While this panel of experts will vote on whether the treatment should be approved, Woodock will ultimately have the final say, with a decision expected before or on May 26. 

As mentioned, SRPT has been halted today, and remains docked at its Friday settlement of $14.95. This closing price capped a huge day to end the week, wiht the stock jumping 35.7%, thanks to buzz surrounding today's FDA meeting. Still, the shares remain 61% lower year-to-date -- and gapped lower last Thursday on speculation surrounding the drug's approval.

As far as sentiment goes, Sarepta Therapeutics Inc (NASDAQ:SRPT) is surrounded by skepticism on Wall Street. For starters, short interest represents almost 43% of the stock's float, while nine out of 13 brokerage firms rate the stock a "hold" or "strong sell." Meanwhile, SRPT's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 0.58 rests just 14 percentage points from an annual high. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1